



Gliadin and Casein Metabolism: Synthesis of Gliadomorphin and Casomorphin and Their Biological Consequences

Rashed AHMED, Md. Tanzimur Rahman TAMIM

Department of Pharmaceutical Sciences, Associate Editor, NSU Journal of Student Research, North South University, Dhaka, Bangladesh

Corresponding author: rashed.ahmed@northsouth.edu

Abstract

Gliadin (from gluten) and casein (from milk) are major dietary proteins that, upon incomplete digestion, yield biologically active opioid peptides known as gliadomorphin and casomorphin, collectively referred to as "exorphins." These peptides are increasingly recognized for their role in numerous physiological and pathological processes, particularly concerning the gut-brain axis. **Methodology and Findings:** This analysis describes the intricate enzymatic hydrolysis of gliadin and casein, resulting in the creation of these opioid peptides. Gliadomorphin and casomorphin are shown to cross the intestinal and blood-brain barriers, subsequently binding to opioid receptors. Their activity influences pain sensitivity, immunity, mood regulation, and mental processing. Emerging evidence suggests their involvement in disease states such as celiac disease, Autism spectrum disorder (ASD), schizophrenia, and irritable bowel syndrome (IBS) through mechanisms involving altered neurotransmission, immune activation, inflammation, oxidative stress, and increased intestinal permeability. **Interventions and future directions:** Current and potential interventions focus on mitigating these harmful effects. Strategies include the consumption of gluten-free and casein-free diets, supplemental enzyme use (e.g., Dipeptidyl Peptidase IV/DPP-IV), modulation of the gut microbiota, and pharmacological interventions like opioid receptor antagonists and zonulin blockers. Future research calls for advanced diagnostic tools and personalized nutrition protocols informed by genetic and microbiome assessments to develop specific therapeutic approaches. The metabolism of gliadin and casein into potent exorphins highlights a critical link between diet and the health of the gut, immune system, and brain. Further study into gliadomorphin and casomorphin development promises novel therapeutic strategies for individuals affected by their biological activity.

Keywords: Gliadomorphin, casomorphin, exorphins, gluten-free and casein-free (GFCCF) diet, opioid receptors

Acknowledgments: Thank you to all parties who supported and helped so that this research could be published.

For citation:

Ahmed, R & Tamim, T. R. (2025). Gliadin and Casein Metabolism: Synthesis of Gliadomorphin and Casomorphin and Their Biological Consequences. *Radinka Journal of Health Science*, 3(2), 486-502.

Introduction

Food proteins, in addition to being nutrients, can be precursors of bioactive peptides participating in physiological processes. In particular, gliadin—a fraction of gluten found in wheat—and casein—the milk protein—undergo enzymatic hydrolysis to form peptides with opioid activity: gliadomorphin and casomorphin, respectively (Ul-Haq, 2020). They have been of interest for their potential effects on the nervous, gastrointestinal, and immune systems. Gliadin is partially undigested in the intestine after oral ingestion, forming gliadomorphin (or gluteomorphin), with the potential to bind to opioid receptors in the brain and other tissues. Casein is broken down to yield casomorphins, such as β -casomorphin-7 (BCM-7), with the same opioid-like effect. The formation and absorption of such peptides can vary based on individual factors, including gut permeability and the activity of gastrointestinal enzymes. The systemic actions of such peptides were investigated in more recent research. A review extensively highlighted that casomorphins and gliadomorphins (another term for gliadomorphin) influence not only the gut and brain, but also the internal organs, suggesting a broad spectrum of biological activity. Additionally, the impact of β -casomorphin-7 on colonic motility has been researched, providing some insight into the way it could affect gastrointestinal function (Khavkin et al., 2022). The therapeutic potential of these peptides has been a subject of active investigation. Casomorphins and gliadomorphins have been implicated by emerging evidence in diseases such as autism spectrum disorders, schizophrenia, and a variety of gastrointestinal disorders. However, the full extent of their impact on human health has yet to be elucidated, necessitating further research. The aim of this article is to review the metabolic pathways to gliadomorphin and casomorphin formation, examine their biological activities, and shed light on the potential health implications of the ingestion of gliadin- and casein-containing foods. By investigating these processes, we can more completely understand the complex interplay between diet, digestion, and health, with the ultimate outcome of more informed dietary habits and therapeutic interventions.

The overall objective of this research is to study the metabolic processes by which gliadin and casein are broken down, leading to the formation of gliadomorphin and casomorphin, respectively. It is necessary to know these processes to uncover the biochemical pathways that produce these opioid-like peptides and their potential impact on human health. By examining the enzymatic breakdown of gliadin and casein, this research aims to provide a comprehensive view of the factors governing peptide formation, absorption, and systemic effect. Another primary objective is to outline the biological actions of gliadomorphin and casomorphin on physiological systems. The peptides have been involved in various disease states, including gastrointestinal disorders, neurological disorders, and immune response. The study seeks to evaluate existing scientific evidence for their potential role in diseases including celiac disease, autism spectrum disorders, and other disorders

ahmed

associated with disrupted gut-brain interactions. Furthermore, the study aims at investigating the broader health consequences of consumption of gliadin- and casein-containing foods in the diet based on inter-individual variations in digestion and absorption of peptides. Studies on the binding of these peptides to opioid receptors and their effects on gut permeability, immune system, and neurological processes will uncover possible risks and advantages of consumption of gluten and dairy products. Lastly, this study aims to contribute to the growing body of knowledge on diet-derived bioactive peptides with data on their potential therapeutic as well as dietary significance. The findings may pave the way for more targeted nutritional recommendations and interventions, especially for individuals with heightened sensitivity to these peptides.

Methodology

This study adopted a mixed-methods research approach, integrating an in-depth literature review and comprehensive online research to determine the metabolic pathways of gliadin and casein,

leading to the formation of gliadomorphin and casomorphin, and their subsequent biological impacts. The use of these approaches gave a broader perspective, allowing the analysis to be derived from diverse sources without undermining scientific integrity. Each method played a vital role in the conceptualization of the topic and in the results overall.

Literature Review

The cornerstone of this research was the literature review, which provided the theoretical and scientific basis for gliadin and casein metabolism. In this phase, peer-reviewed articles, scientific journals, books, and authoritative reports regarding gliadin and casein digestion, opioid peptide formation, and their physiological impact were collected, evaluated, and synthesized systematically (Liu & Udenigwe, 2019). A strict search strategy was employed over prestigious academic databases including PubMed, ScienceDirect, Scopus, and Google Scholar. The keywords "gliadin metabolism," "casein hydrolysis," "gliadomorphin," "casomorphin," "opioid peptides," and "gut-brain axis" were utilized to find pertinent studies. The selection criteria included papers published within the last two decades to encompass the latest findings as well as seminal papers that presented the theoretical foundations of peptide formation and absorption mechanisms. Particular interest was placed on studies investigating the enzymatic pathways of gliadin and casein degradation and also on studies following the health consequences of gliadomorphin and casomorphin. Manuscripts discussing gastrointestinal function, immune modulation, and neurological effects were prioritized. Findings from animal studies, human clinical trials, and in vitro experiments were carefully considered for their significance on the overall physiological impact of these opioid peptides (Stefanucci et al., 2018) only could the literature review allow general themes and gaps in existing research to be determined, it also allowed a conceptual model of how the biological effects of these peptides can be examined to be developed. This step, in bringing together facts from a multitude of sources, allowed an overview of the metabolic processes behind gliadomorphin and casomorphin formation.

Online Research

To augment the literature review, online research was conducted to derive updated information, recent debates, and other opinions that may not have been available in peer-reviewed literature. This phase aimed to gather information from recent research, expert opinions, and reputable health institutions (Sridhar Anakal & S. Soumya, 2024). Online databases, scientific forums, health websites, and official reports of organizations like the World Health Organization (WHO) and the Food and Agriculture Organization (FAO) were consulted. Research repositories, preprint servers, and discussion forums like ResearchGate and Academia.edu also provided access to ongoing research and projects in progress. The online research phase was geared towards establishing pragmatic implications, existing findings, and patient-centered insights on the consumption of gliadin- and casein-containing foods. This encompassed examining anecdotal evidence, formulating hypotheses, and public health recommendations on gluten and dairy consumption. Online databases were also used in keeping abreast of ongoing controversies on the potential links of these peptides to health conditions like autism spectrum disorders, schizophrenia, and gut-brain axis dysfunctions (Autore & De, 2021).

Mixed Methodology Implementation

The mixed-method approach integrated the contribution of the literature review and the online research, creating a methodologically rigorous design that provided breadth and depth to the investigation. Data collection involved sorting the gathered information into thematic groups: metabolic pathways, health implications, and therapeutic potential. Each theme was researched independently and cross-checked with the findings of other sources for reliability and consistency.

Comparative analysis was conducted to identify patterns and contrasts between existing studies, enabling discrepancies, consensus, and gaps in knowledge to be highlighted. This enabled synthesis of differing perspectives, creating a more complex picture of complex processes involved in the formation of gliadomorphin and casomorphin and their implications for general health (Woodford, 2021). By employing a mixed-method design, the study not only enhanced its analysis but also rendered its conclusions more balanced and supported by various strands of evidence. The integration of various data sources facilitated the incremental investigation of the topic, revealing new insights into the metabolic and physiological roles of gliadin and casein peptides.

Results and Discussion

Historical Aspects

The past of the investigation of the metabolism of gliadin and casein, and the discovery of their opioid peptide-like products—gliadomorphin and casomorphin—is one of decades of investigation and framed by major developments in protein chemistry, enzymology, and medicine. The journey of discovery of the subtle interaction between diet, digestion, and health reflects the process of developing major advancements in these areas as researchers gradually untangled the process (Zhu, 2024). The search for gluten and dairy proteins started as far back as the 19th century when wheat gluten was discovered and purified based on its exceptional viscoelastic nature. It is only with the early 20th century that the fundamental understanding of gliadin, one particular fraction of proteins in gluten, was obtained. Initial research focused on the role of gluten in celiac disease, which was first described by British physician Samuel Gee in 1888. Gee's observations served as the foundation for later research into gluten disorders. In the 1950s, the first advance into linking the ingestion of gluten with celiac disease was made by Dutch pediatrician Willem-Karel Dicke, which stimulated increased interest in the metabolic processes of gluten digestion (Braconi et al., 2018). By the 1970s, the theory of opioid peptides — called exorphins — from food proteins started to gain traction. Scientists during this time found that the partial digestion of gliadin resulted in peptides with opioid activity, later characterized as gliadomorphins (also called gluteomorphins). The peptides were found to bind with opioid receptors within the nervous system, which hinted at possible effects beyond digestion. Around the same time, research on milk proteins discovered similar mechanisms, where digestion of casein produced casomorphins, a group of peptides with potential to bind to opioid receptors. In 1979, Zioudrou et al. introduced in a seminal paper the term "exorphins" — peptides derived from food protein having an equivalent action as endorphins, the body's own opioids. This research fanned further interest in whether and how these dietary peptides could influence brain function, behavior, and health. Throughout the following decades, scientists built on research of the physiological actions of gliadomorphins and casomorphins to evaluate their functions in modulating gut motility, immune function, and potential relations to neurological disorders. In the early 2000s, studies of the gut-brain axis accelerated, revealing the intricacies of communication between the central nervous system and the gut. Theoretical frameworks proposed that increased intestinal permeability — better referred to as "leaky gut" — could facilitate the entry of opioid peptides from the gut lumen into the bloodstream, where they could cross the blood-brain barrier and affect brain function. This hypothesis evoked growing interest into the potential activities of gliadomorphins and casomorphins in conditions such as autism spectrum diseases, schizophrenia, and chronic inflammatory diseases (Dhar, 2024). Recent work continues to examine the broader implications of these peptides. Experiments have examined the genetic determinants of gluten and casein hydrolysis and microbial activity within the gut. The increasing exploration of gliadin and casein metabolism is a fascinating intersection of nutrition, immunology, neuroscience, and microbiology with implications for personalized medicine and diet treatment. The historical trajectory of gliadomorphin and casomorphin research not only illustrates scientific investigation but also serves to highlight the evolving understanding of how proteins consumed impact human health. As research continues to

advance, the understanding gained may result in the creation of specific treatments and dietary recommendations to avoid potential adverse effects of these opioid-like peptides.

Gliadin: Structure and Metabolism

Gliadin is one of the major protein fractions of gluten, which is mainly found in wheat and related cereals like barley and rye. Gliadin is characterized by proline and glutamine residues, which make it resistant to complete digestion by human gut enzymes. Digestion begins upon ingestion of foodstuffs with gluten in the stomach with pepsin and continues in the small intestine with pancreatic enzymes like trypsin and chymotrypsin. However, due to the large amount of proline, gliadin is partially hydrolyzed into shorter peptide fragments rather than being fully degraded to amino acids (Herrera et al., 2014). In this partial hydrolysis, certain peptides known as gliadomorphins or gluteomorphins) are formed. These opioid peptides possess sequences of similar structure to endogenous opioids, such as endorphins, and hence can bind to opioid receptors within the nervous system. One of the significant gliadomorphin peptides is Gliadorphin-7, a seven-amino-acid peptide that is formed when gliadin is partially hydrolyzed by pepsin and pancreatic enzymes (Di Cagno et al., 2002).

Gliadin to Gliadomorphin Pathway and Mechanism of Action

Gliadomorphin formation is a consequence of proteolytic hydrolysis of gliadin by such enzymes as pepsin in the stomach and pancreatic enzymes in the small intestine. Such gliadin-derived peptides that are formed may be capable of passing through the small intestinal epithelial barrier, especially in individuals with greater intestinal permeability or "leaky gut." Upon being taken up by the bloodstream, gliadomorphins can bind to opioid receptors in peripheral tissues and even gain access to the brain through crossing of the blood-brain barrier. Following binding to opioid receptors — predominantly the μ -opioid receptors — these peptides can potentially modulate pain perception, immune reactions, and neurotransmission. Gliadomorphins are considered to influence mood, behavior, and cognition and in susceptible subjects contribute to neurological and psychiatric illness (Pomorska et al., 2015).

Casein: Structure and Metabolism

Casein is the primary milk and dairy protein and accounts for about 80% of milk proteins. Similar to gliadin, casein is a hard structure to digest and thus is resistant to complete digestion. Casein also exists in different forms, β -casein being important in casomorphin synthesis, opioid peptides that are formed as a result of casein breakdown. Casein breakdown is begun in the stomach by the action of pepsin, which cleaves casein into peptides. Hydrolysis is continued during further digestion in the small intestine by pancreatic enzymes like trypsin and chymotrypsin (DiMagno, 1990). Among the large fragments produced in the process is β -casomorphin-7 (BCM-7), a seven-amino-acid peptide with opioid activity. BCM-7 formation is also influenced by the genetic variant of β -casein in the milk; A1-type β -casein, found in some breeds of cows, is more prone to produce BCM-7 than A2-type β -casein.

Casein to Casomorphin Pathway and Mechanism of Action

Synthesis of casomorphins occurs through the enzyme-catalyzed hydrolysis of β -casein, particularly by pepsin and pancreatic proteases. Upon synthesis, casomorphins may be absorbed across the intestinal epithelium, particularly in subjects with increased intestinal permeability. After being transported into the blood, casomorphins can act on opioid receptors, the effects being similar to those induced by gliadomorphins. Casomorphins primarily exert action on the μ -opioid receptors,

modulating pain sensation, gut motility, and the immune response. Casomorphins are postulated to retard digestion through the inhibition of gut motility, which would cause constipation in susceptible subjects. The peptides may also produce neuromodulatory effects on mood, cognition, and behavior through their action on opioid receptors within the central nervous system (Griffith & La France, 2018).

Comparative Insights and Biological Implications

Both casomorphins and gliadomorphins act upon opioid receptors, potentially influencing pain, mood, and immune system function. Their production during digestion indicates the complexity of protein metabolism and their potential roles in health and disease. Research has linked these peptides with autism spectrum disorder, schizophrenia, and autoimmune illness, fueling controversy about the potential therapeutic effect of gluten-free and dairy-free diets in these conditions. Together, the metabolic processes of gliadin and casein and their conversion to biologically active peptides capture the intricate relationship between diet, digestion, and health. With further research, greater insight into these processes could open up new avenues for therapeutic interventions and dietary options (Chiarelli et al., 2024).




Figure 1. Dietary proteins and health implications

Health Effects of Gliadomorphins and Casomorphins

The synthesis of gliadomorphins and casomorphins during the digestion of gliadin and casein has been linked to several physiological and neurological effects. These opioid peptides can potentially influence the body in complex ways, primarily through their effect on μ -opioid receptors in the gut, blood, and brain. Let's discuss the most significant health effects in greater detail:

1. Neurological Effects

Gliadomorphins and casomorphins are also able to cross the blood-brain barrier, where they can control brain function through activity at opioid receptors. They are able to affect mood, thinking, and behavior and have been increasingly linked to a range of neurological and psychiatric illnesses:

a. Autism Spectrum Disorder (ASD):

Research has shown that children with ASD may have higher levels of gliadomorphins and casomorphins in their urine, indicating increased absorption of these peptides. The "opioid excess theory" suggests that the peptides may disrupt normal neural function and result in compromised social interaction, repetitive behavior, and sensory processing problems.

b. Schizophrenia:

Individuals with schizophrenia have been reported to exhibit higher levels of opioid peptides, which can aid in abnormal regulation of dopamine and cognitive impairment.

c. Mood Disorders:

Gliadomorphins and casomorphins can also influence mood by altering neurotransmitter release. Their opioid action can induce euphoria or, conversely, lead to depression and anxiety by upsetting the endorphin and other neurotransmitter balance.

2. Gastrointestinal Effects

Both gliadomorphins and casomorphins are active at opioid receptors in the gut, with effects on digestion and motility:

a. Reduced Gut Motility:

Activation of opioid receptors slows peristalsis — the rhythmic muscular contractions of the digestive system that move food through the intestines. This can lead to constipation, bloating, and abdominal discomfort.

b. Increased Intestinal Permeability ("Leaky Gut"):

In some individuals, gliadin peptides have the ability to induce the release of zonulin, a protein that modulates tight junctions between cells in the intestines. If these junctions are "leaky," undigested peptides like gliadomorphins and casomorphins may enter the blood, potentially triggering immune responses or systemic inflammation.

c. Altered Microbiome:

Recent evidence shows that gliadin and casein digestion can impact the balance of gut microbiota, which plays a crucial role in immune regulation and overall health.

3. Modulation of the Immune System

These peptides are able to modulate the immune system directly, particularly gliadomorphins:

a. Autoimmune Diseases:

In genetically susceptible individuals, gliadin peptides are able to activate T-cells and other immune processes to induce autoimmune disease states such as celiac disease and type 1 diabetes.

b. Chronic Inflammation:

Gliadin and casein peptides are able to induce low-grade inflammation by inducing the release of pro-inflammatory cytokines, potentially resulting in chronic inflammatory diseases.

4. Effects on the Endocrine and Metabolic Systems

Current evidence suggests that these peptides may influence hormone release and metabolism:

a. Control of Hunger:

Opioid peptides are capable of altering appetite by acting upon receptors located in the hypothalamus, which is the part of the brain responsible for hunger. The effect can manifest as overindulgence in food or excessive desire for food, particularly for gluten and milk.

b. Insulin Resistance and Metabolic Syndrome:

Casomorphins, in particular, have been linked with aberrant insulin signaling, and their role in metabolic disorders such as type 2 diabetes is of concern.

5. Pediatric and Developmental Problems

Children and infants are particularly vulnerable to the effects of these peptides because they possess less advanced digestive systems and less competent intestinal barriers:

a. Infant Casein Digestion:

Digestion of β -casein in infants, especially those consuming A1 cow's milk, leads to the creation of β -casomorphin-7 (BCM-7), which has effects on respiratory health, immune status, and neurodevelopment.

b. Neurodevelopmental Effects:

Repetitive exposure to opioid peptides during early life may influence brain development and affect cognitive and social skills.




Figure 2. Effects of gliadomorphins and casomorphins

Critical Analysis:

Gliadin and casein metabolism to opioid peptides gliadomorphin and casomorphin has also generated some passionate scientific debates in the context of potential human health consequences. Critical examination of the current literature highlights a number of intriguing issues as areas of concern as well as contention, including biochemical reactions, the resultant health consequences, and experimental limitations of current research.

1. Biochemical Complications and Heterogeneity Between Individuals

The metabolic pathway leading to the production of gliadomorphin and casomorphin is complex and influenced by numerous factors, such as genetic predisposition, gut microbiota composition, and intestinal permeability. Significantly, the cleavage of gliadin and casein is not always fruitful for the generation of these peptides in all subjects. For instance, individuals with impaired function of digestive enzymes — for instance, reduced dipeptidyl peptidase IV (DPP-IV) activity — may have incomplete protein digestion, with a higher level of these opioid peptides appearing in the circulation. Furthermore, "leaky gut syndrome" would enable passage of these peptides through the intestinal membrane, once more enhancing their biological activity (Nascimento et al., 2022). Yet, not all studies take this variation into consideration, making sweeping generalizations across heterogeneous populations without regard to the impact of genetic predispositions, dietary lifestyles, or concurrent health conditions. This makes reproducibility and

generalizability of findings problematic. Future research would be wise to stratify participants according to these variables in order to create a more representative picture of gliadin and casein metabolism.

2. Neurological and Behavioral Implications: Correlation vs. Causation

A growing body of evidence links gliadomorphins and casomorphins with neurological conditions such as autism spectrum disorder (ASD), schizophrenia, and attention deficit hyperactivity disorder (ADHD). The "opioid excess theory" proposes that these peptides, once they have crossed the blood-brain barrier, may bind to opioid receptors and disrupt neurotransmitter equilibrium. Some have reported elevated urine concentrations of gliadomorphins and casomorphins in ASD patients, which suggests abnormal peptide metabolism (Tarnowska et al., 2023). However, the evidence remains largely correlational. Critics argue that most of these studies are poorly controlled, and confounding factors such as diet, microbiome composition, and environmental exposures are not controlled for. Furthermore, the blood-brain barrier in healthy individuals is relatively selective, so it is unclear whether these peptides consistently reach the central nervous system in quantities adequate to produce measurable effects. Further studies with novel imaging technologies and animal models must be done to clarify this potential mechanism.

3. Interactions between Gastrointestinal System and Immune System

Gliadin peptides are proposed to induce increased intestinal permeability by stimulating the release of zonulin, a modulator of tight junctions between intestinal epithelial cells. In individuals with a genetic predisposition, such as those with celiac disease, this may stimulate an immune response, with subsequent chronic inflammation and intestinal injury. Casomorphins would, however, modulate the immune response and gut motility by interacting with opioid receptors of the gut. While these observations account for the gut-brain axis, studies are mostly based on extreme cases, such as celiac disease or cow's milk protein allergy. There is not sufficient evidence to draw conclusions about the negative effects of gliadomorphins and casomorphins in healthy individuals. Investigations examining these interactions in larger more heterogeneous populations are critical to fully determining the spectrum of responses to these peptides (Ahmed & Tanzimur Rahman Tamim, 2025).

4. Methodological Problems and Bias

The techniques employed in research on the synthesis and uptake of gliadomorphin and casomorphin are often seriously flawed. The majority of studies rely on urine and blood samples as the foundation for peptide quantification, which may not be representative of activity at the cellular or receptor level. In addition, peptide detection assays such as ELISA (enzyme-linked immunosorbent assay) may cross-react with other proteins, resulting in potential false-positive findings. The second issue is employing in vitro studies or animal models, which may not mirror the human metabolic system. The structural features of human digestion and role of diverse gut microbiota are difficult to reproduce in a lab environment. Such loopholes in methodology have to be sealed for the robustness of such follow-up studies (Ahmed, 2025).

5. Therapeutic and Dietary Implications

Despite controversies, research on gliadomorphins and casomorphins presents the possibility of individualized nutrition and therapeutic strategies. Gluten-free and A1 casein-free diets are increasingly popular, with anecdotal reports of symptom alleviation in disorders such as ASD, irritable bowel syndrome (IBS), and other inflammatory disorders. The scientific literature is,

however, contradictory to these dietary strategies, with some studies showing improvements and others finding no measurable effects (Zafirovski et al., 2024). Future research would aim to establish positive biomarkers of casomorphin and gliadomorphin action and address the long-term ramifications of diet changes. In addition, exploring enzyme treatments for enhanced peptide breakdown could open up alternative options for the control of potential side effects. The hydrolysis of gliadin and casein into casomorphins and gliadomorphins presents intriguing possibility for the unraveling of dietary, digestive, and health relations. But existing studies are marred by heterogeneity, methodology, and problems in distinguishing cause from correlation. It is through properly designed large-scale studies incorporating genetic, microbiome, and environmental factors that the actual consequences of these opioid peptides can truly be fully evaluated, guiding dietetic recommendations as well as drug development (Reissmann, 2020).

Potential Interventions

Some of the possible interventions are being found to be effective therapies for reversing the effect of gliadomorphins and casomorphins. The most widely used intervention is gluten-free and casein-free (GFCF) diets. GFCF diets have been found to yield anecdotal relief in reducing symptoms in individuals with ASD, celiac disease, and other conditions linked to opioid peptide activity. Future studies must test these assertions using rigorously designed clinical trials to make dietary advice evidence-based (Foxy & Mulick, 2015). Enzyme therapy is another treatment of interest, particularly with the use of dipeptidyl peptidase IV (DPP-IV) supplements. DPP-IV is an enzyme that facilitates the breakdown of gluten and casein-derived peptides, perhaps reducing the formation of gliadomorphins and casomorphins. Supplementing with DPP-IV or preparing enzyme blends formulated to enhance peptide digestion may offer a effective solution for those with incomplete protein digestion (Elder et al., 2015). Gut health modulation is also a fascinating intervention approach. Probiotic and prebiotic therapies that selectively address gut bacterial strains could help improve protein digestion and reduce opioid peptide formation. Additionally, fecal microbiota transplantation (FMT) is a more recent intervention that can possibly achieve balance within the gut microbiota, improving digestion and reducing peptide formation. Pharmacologic interventions targeting opioid receptors offer another possible avenue for diminishing the effects of these peptides. Opioid receptor antagonists, such as low-dose naltrexone (LDN), can potentially block the binding of gliadomorphins and casomorphins to opioid receptors, reducing their neurological and gastrointestinal effects. Furthermore, research into zonulin inhibitors to maintain intestinal barrier integrity can keep the peptides from entering the bloodstream and reaching the central nervous system (Wageningen University & Research & Fj Savelkoul, 2017). Public health interventions for the raising of awareness and improved labeling of food could also play a role. Clear labeling of the content of gluten and casein, and proper education regarding the potential effect of such proteins, could allow participants to make improved dietary decisions. With improved diagnostic testing, such programs would offer timely intervention and improved health outcomes among those sensitive to these peptides. To sum up, the future is bright for understanding and preventing the health impact of gliadomorphins and casomorphins. With personalized nutrition, enzyme therapy, microbiome modulation, and pharmacological treatment, at-risk individuals may be assisted by a range of highly targeted interventions. With ongoing research, these interventions have the potential to lead to an opening up of the door to improved management of conditions associated with the opioid peptides, ultimately improving quality of life for sufferers (Saad et al., 2024).

1. Personalized Nutrition and Diet Modification

One of the most immediate applications of understanding gliadomorphin and casomorphin metabolism is the development of personalized nutritional strategies. Individuals with heightened vulnerability to these peptides, such as celiac disease, non-celiac gluten sensitivity, cow's milk protein intolerance, or neurological dysfunction, can benefit from diet modification based on individual requirements.

a. Gluten-Free and Casein-Free Diets (GFCF):

Dietary removal of gluten and casein has been gaining popularity, especially among parents of autistic spectrum disorder (ASD) children and individuals with gastrointestinal problems. While there is anecdotal and some scientific evidence for symptom improvement, large controlled studies are required to establish these effects and also to identify biomarkers for responsiveness to these diets.

b. A2 Milk as an Alternative:

In the case of casein, consumption of A2 milk — which lacks the β -casein variant that causes the production of β -casomorphin-7 (BCM-7) — may offer a safer alternative for individuals sensitive to casomorphins. Comparison of the effects of A1 versus A2 milk in research may also reveal whether this intervention is effective.

2. Enzyme Supplementation Therapy

Enzyme supplementation therapy is another promising intervention, where enzyme supplements are consumed to aid digestion and block the synthesis of toxic opioid peptides.

a. Dipeptidyl Peptidase IV (DPP-IV) Supplements:

DPP-IV is a key enzyme that digests proline-rich peptides like gliadin and casein-derived peptides. Supplementing with DPP-IV enzymes can enhance the breakdown of gliadin and casein, reducing the formation of gliadomorphin and casomorphin and perhaps minimizing symptoms in susceptible individuals.

b. Proteolytic Enzyme Blends:

Combining DPP-IV with other proteolytic enzymes can be more beneficial by allowing more complete protein digestion, minimizing the formation of immunogenic and opioid peptides.

3. Microbiome and Gut Health Modulation

The gut microbiome plays a role in peptide metabolism and immune modulation. Future interventions can be developed to modulate the microbiome to neutralize the effects of gliadomorphin and casomorphin production.

a. Probiotics and Prebiotics:

Some probiotic strains, such as *Lactobacillus* and *Bifidobacterium*, have shown promise in enhancing peptide degradation and improving intestinal tightness. Prebiotics, which promote the growth of beneficial bacteria, may also augment this action by creating a more conducive gut environment.

b. Fecal Microbiota Transplantation (FMT):

In advanced gut dysbiosis (gut microbial imbalance), FMT may have a radical but helpful intervention. By restoring the balanced microbiome, FMT could potentially improve peptide metabolism and alleviate symptoms thereof.

4. Pharmacological Interventions

Pharmacological interventions can be considered in individuals with severe neurological or gastrointestinal symptoms related to gliadomorphins and casomorphins.

a. Opioid Receptor Antagonists:

Opioid receptor-inhibiting drugs, such as naltrexone and naloxone, can reverse the effects of gliadomorphins and casomorphins on the brain and intestine. LDN is already being researched in the context of diseases like fibromyalgia and Crohn's disease, with the possibility of reducing inflammation and immune modulation.

b. Zonulin Inhibitors:

Medications against zonulin, a protein that plays a role in increasing intestinal permeability, can prevent gliadin peptides from crossing the intestinal barrier and entering circulation. Larazotide acetate, an inhibitor of zonulin, is under study as a treatment for celiac disease and has potential broader application in peptide disease.

5. Public Health Initiatives and Education

Raising awareness of the likely activities of gliadomorphins and casomorphins can allow individuals to make informed dietary choices. Public health initiatives can focus on:

a. Nutritional Education:

Educating healthcare professionals and the public about the likely activities of gluten and casein metabolism can help in the early identification and management of related health complications.

b. Food Labeling and Regulation:

Improved labeling of gluten and casein levels in processed food can help individuals on restrictive diets and minimize unintentional exposure.

Future Directions

The future of the research on gliadin and casein metabolism is vast with far-reaching implications in the understanding of the complexity of dietary-digestion health interactions. One of the most important areas of future research is individualized nutrition. With scientific discoveries about the genes, microbiome, and metabolomics that are involved in the release of gliadomorphins and casomorphins, individualized dietary programs may be achieved. The development of genetic screening mechanisms to identify individuals who may be at higher risk for enhanced opioid peptide production can pave the way for selective nutritional guidance so that those at risk can implement those diets that minimize potential effects on health (Singar et al., 2024). Another possibility that is exciting is the use of advanced diagnostic techniques to quantify the presence and levels of the opioid peptides in biologic samples. Future research might include the development of biomarkers that uncover a person's metabolic response to gliadin and casein, enabling the early detection of abnormal peptide function. Longitudinal research that tracks eating patterns and health over the years could also provide helpful data on the long-term effects of gliadomorphins and casomorphins on neurological, gut, and immune well-being. These findings would give more targeted information for dietary guidance and treatment regimens aimed directly at those most affected (Ahmed, 2024). Greater exploration of the gut-brain axis, more precisely, how these peptides modulate neurological function, represents another critical realm. Studies combining neuroimaging techniques and behavior

assessments might more effectively clarify the suspected role for gliadomorphins and casomorphins in pathologies like ASD, schizophrenia, and mood disorder. Clarification of these relations may not merely account for the peptides' action on brain activity but also assist in the design of novel treatment strategies (Nilsson et al., 2019). The topic of gliadin and casein metabolism requires further study to fully understand the long-term health effects and potential treatments. Potential areas for future research include:

a. Determining Biomarkers:

Development of efficacious biomarkers that can adequately quantify levels of gliadomorphin and casomorphin in blood, urine, or cerebrospinal fluid would allow early diagnosis and appropriate interventions (Shahnawaz & Soto, 2021).

b. Longitudinal Studies:

Large-scale, long-term studies are suggested to assess the effect of dietary change, enzyme supplementation, and microbiome modulation on the health outcomes, which would provide the answer to the question regarding the effectiveness of these interventions.

c. Study of Genetic Susceptibility:

Studies of genes influencing peptide production and uptake may provide opportunities for personalized medicines.

Conclusion

The digestion of gliadin and casein, which leads to the formation of gliadomorphin and casomorphin, is an interesting place where nutrition, biochemistry, and health converge. As this article has explored, these opioid peptides have some very important impacts on the gastrointestinal, immune, and nervous systems. That gliadomorphins and casomorphins can pass through intestinal and blood-brain barriers and attach to opioid receptors has led to the realization of an increased need to understand how such structures have functions in numerous medical diseases. They affect not only the health of the gut and immune functions but are involved with possible contribution of neurologic disease as well. History, in research into metabolism of gliadin and casein, has helped push knowledge into body response to the proteins. Research that identifies these peptides with diseases such as celiac disease, autism spectrum disorder (ASD), and other inflammatory and neurological disorders makes the investigation of dietary etiology of disease control and progression especially important. With increasing science shedding light on the intricate mechanism through which the peptides are formed and how they interact with the body, other questions now remain regarding their long-term effects and the ways through which they can be avoided. Moreover, the health effects of gliadomorphin and casomorphin production have created a window of opportunity for a range of interventions, such as gluten-free and casein-free diets, enzyme therapies, and microbiome modulation. Individualized nutrition approaches offer promising options for those at risk for these peptides, potentially reducing symptoms and improving well-being. Pharmacological treatments that target opioid receptors and improve gut barrier function also provide new treatment options. The future of research on gliadin and casein metabolism is bright. Advances in technical diagnostic tests, biomarkers, and genetic screening will, in the not-too-distant future, allow for the identification of susceptible individuals with even greater specificity. Further long-term follow-up studies will help to establish the efficacy of interventions currently practiced as well as uncover new forms of therapy. With growing knowledge and scientific inquiry, the hope is that effective holistic approaches will be

developed to counteract the diverse health consequences of these peptides. In short, understanding how gliadin and casein are broken down is not just a matter of food selection but health and disease regulation. As scientists and physicians continue to explore the complexities of these biological mechanisms, more effective interventions can be created, which will improve the quality of life for patients and open the door for future advances in nutrition, medicine, and other fields.

Conflicts of Interest

No conflict of interest.

References

- Ahmed, R. (2024). *Cyber Harassment in the Digital Age: Trends, Challenges, and Countermeasures*. Computer Science and Mathematics. <https://doi.org/10.20944/preprints202409.1882.v1>
- Ahmed, R. (2025). Human Metapneumovirus (HMPV): Epidemiology, Pathophysiology, Clinical Management, and Future Prospects in Treatment and Prevention. *RADINKA JOURNAL OF HEALTH SCIENCE*, 2(3), 312–327. <https://doi.org/10.56778/rjhs.v2i3.417>
- Ahmed, R. & Tanzimur Rahman Tamim. (2025). Enhancing Medication Safety: The Role of Community and Hospital Pharmacists in Modern Healthcare Systems. *RADINKA JOURNAL OF HEALTH SCIENCE*, 2(3), 328–355. <https://doi.org/10.56778/rjhs.v2i3.418>
- Autore, S., & De, S. (2021). *Effects of COVID-19 on Global Healthcare Research and Management*. <https://doi.org/10.21467/preprints.314>
- Braconi, D., Bernardini, G., Millucci, L., & Santucci, A. (2018). Foodomics for human health: Current status and perspectives. *Expert Review of Proteomics*, 15(2), 153–164. <https://doi.org/10.1080/14789450.2018.1421072>
- Chiarelli, R., Caradonna, F., & Naselli, F. (2024). Autophagy and nutrigenomics: A winning team against chronic disease and tumors. *Frontiers in Nutrition*, 11, 1409142. <https://doi.org/10.3389/fnut.2024.1409142>
- Dhar, P. (2024). Advanced nutritional research from a physiological standpoint. *INDIAN JOURNAL OF PHYSIOLOGY AND ALLIED SCIENCES*, 76(01), 4–8. <https://doi.org/10.55184/ijpas.v76i01.212>
- Di Cagno, R., De Angelis, M., Lavermicocca, P., De Vincenzi, M., Giovannini, C., Faccia, M., & Gobbetti, M. (2002). Proteolysis by Sourdough Lactic Acid Bacteria: Effects on Wheat Flour Protein Fractions and Gliadin Peptides Involved in Human Cereal Intolerance. *Applied and Environmental Microbiology*, 68(2), 623–633. <https://doi.org/10.1128/AEM.68.2.623-633.2002>
- DiMagno, E. P. (1990). Fate of Pancreatic Enzymes During Gastrointestinal Transit. In H. G. Beger, M. Büchler, H. Ditschuneit, & P. Malfertheiner (Eds.), *Chronic Pancreatitis* (pp. 144–146). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-75319-0_17
- Elder, J., Kreider, C., Schaefer, N., & deLaosa, M. (2015). A review of gluten- and casein-free diets for treatment of autism: 2005–2015. *Nutrition and Dietary Supplements*, 87. <https://doi.org/10.2147/NDS.S74718>
- Foxx, R. M., & Mulick, J. A. (Eds.). (2015). The Gluten-Free, Casein-Free Diet. In *Controversial Therapies for Autism and Intellectual Disabilities* (0 ed., pp. 430–441). Routledge. <https://doi.org/10.4324/9781315754345-35>
- Griffith, C., & La France, B. (2018). Neuro Effects of Opioids on the Human Brain. *Biochemistry and Modern Applications*, 6–8. <https://doi.org/10.33805/2638-7735.113>
- Herrera, M. G., Zamarreño, F., Costabel, M., Ritacco, H., Hütten, A., Sewald, N., & Dodero, V. I. (2014). Circular dichroism and electron microscopy studies in vitro of 33-mer gliadin peptide revealed secondary structure transition and supramolecular organization. *Biopolymers*, 101(1), 96–106. <https://doi.org/10.1002/bip.22288>

- Khavkin, A. I., Vasia, M. N., & Novikova, V. P. (2022). The biological role of casomorphins (part 2): Role in human pathology. *Experimental and Clinical Gastroenterology*, 12, 110–118. <https://doi.org/10.31146/1682-8658-ecg-196-12-110-118>
- Liu, Z., & Udenigwe, C. C. (2019). Role of food-derived opioid peptides in the central nervous and gastrointestinal systems. *Journal of Food Biochemistry*, 43(1), e12629. <https://doi.org/10.1111/jfbc.12629>
- Nascimento, H. H. S., Oliveira, V. H. L. D., Reis, E. B. B. D., Souza, D. M., & Ferreira, M. B. (2022). Leaky gut – terapêutica e tratamento da síndrome do intestino permeável: Uma revisão bibliográfica. *Research, Society and Development*, 11(16), e513111638739. <https://doi.org/10.33448/rsd-v11i16.38739>
- Nilsson, P. D., Newsome, J. M., Santos, H. M., & Schiller, M. R. (2019). Prioritization of Variants for Investigation of Genotype-Directed Nutrition in Human Superpopulations. *International Journal of Molecular Sciences*, 20(14), 3516. <https://doi.org/10.3390/ijms20143516>
- Pomorska, D., Gach, K., & Janecka, A. (2015). Immunomodulatory Effects of Endogenous and Synthetic Peptides Activating Opioid Receptors. *Mini-Reviews in Medicinal Chemistry*, 14(14), 1148–1155. <https://doi.org/10.2174/1389557515666150101095237>
- Reissmann, A. (2020). Gluten-free and casein-free diets in the management of autism spectrum disorder: A systematic literature review. *Movement and Nutrition in Health and Disease*, Vol. 4 (2020). <https://doi.org/10.5283/MNHD.9>
- Saad, K., Shabaan, I., Hassan, A.-E.-M. M., Ezzat, M., Abouzed, M. A., Hamed, Y., Ibrahim, M. F. M., & Gad, E. F. (2024). Gluten-Free, Casein-Free Diet for Children with Autism Spectrum Disorder: A Case-Controlled Study. *Journal of Pharmacy and Bioallied Sciences*, 16(Suppl 1), S905–S908. https://doi.org/10.4103/jpbs.jpbs_1074_23
- Shahnawaz, M., & Soto, C. (2021). Identification of biomarkers for diagnosing and monitoring therapy in the treatment of neurologic disorders. In *Neurotherapeutics in the Era of Translational Medicine* (pp. 291–310). Elsevier. <https://doi.org/10.1016/B978-0-12-816475-4.00020-3>
- Singar, S., Nagpal, R., Arjmandi, B. H., & Akhavan, N. S. (2024). Personalized Nutrition: Tailoring Dietary Recommendations through Genetic Insights. *Nutrients*, 16(16), 2673. <https://doi.org/10.3390/nu16162673>
- Sridhar Anakal & S. Soumya. (2024). Literature Review: The Use of AI in Healthcare. *Journal of Scientific Research and Technology*, 81–84. <https://doi.org/10.61808/jsrt143>
- Stefanucci, A., Mollica, A., Macedonio, G., Zengin, G., Ahmed, A. A., & Novellino, E. (2018). Exogenous opioid peptides derived from food proteins and their possible uses as dietary supplements: A critical review. *Food Reviews International*, 34(1), 70–86. <https://doi.org/10.1080/87559129.2016.1225220>
- Tarnowska, K., Gruczyńska-Sękowska, E., Kowalska, D., Majewska, E., Kozłowska, M., & Winkler, R. (2023). The opioid excess theory in autism spectrum disorders—Is it worth investigating further? *Critical Reviews in Food Science and Nutrition*, 63(19), 3980–3993. <https://doi.org/10.1080/10408398.2021.1996329>
- Ul Haq, M. R. (2020). Significant Food-Derived Opioid Peptides. In M. R. Ul Haq, *Opioid Food Peptides* (pp. 1–20). Springer Singapore. https://doi.org/10.1007/978-981-15-6102-3_1
- Wageningen University & Research, & Fj Savelkoul, H. (2017). Treating Autism Spectrum Disorder with Gluten-Free and Casein-Free Diet: The Underlying Microbiota-Gut-Brain Axis Mechanisms. *Clinical Immunology & Immunotherapy*, 3(1), 1–11. <https://doi.org/10.24966/CIIT-8844/100009>
- Woodford, K. B. (2021). Casomorphins and Gliadorphins Have Diverse Systemic Effects Spanning Gut, Brain and Internal Organs. *International Journal of Environmental Research and Public Health*, 18(15), 7911. <https://doi.org/10.3390/ijerph18157911>

- Zafirovski, K., Aleksoska, M. T., Thomas, J., & Hanna, F. (2024). *Impact of Gluten-Free and Casein-Free diet on the quality of life of Autistic children and Adolescents: A Scoping review*. Public Health and Healthcare. <https://doi.org/10.20944/preprints202405.2068.v1>
- Zhu, C. H. (2024). Advances in Research on the Relationship between Diet, Gut Microbes, and Health. *Journal of Clinical and Nursing Research*, 8(8), 213–217. <https://doi.org/10.26689/jcnr.v8i8.7712>